Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Jeffrey G. Black, insider at Apollo Endosurgery
Jeffrey G. Black Insider Alerts

Get notified the next time Jeffrey G. Black buys or sells Apollo Endosurgery stock. Enter your email address below to get our daily insider buying and selling report.

Jeffrey G. Black Insider Information

Jeffrey G. Black was named Chief Financial Officer in August 2021. Mr. Black has served in senior finance leadership roles for seven publicly-traded companies, most recently as Executive Vice President and Chief Financial Officer of Alphatec Holdings, Inc. (ticker: ATEC), a medical technology company. Previously, Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a non-invasive, proteomics-based diagnostics company, and as Chief Financial Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company. Mr. Black is a Certified Public Accountant (inactive) and is a member of the Board of Directors of Cellana, Inc., an algae bioproducts company. Mr. Black received his B.S. in Business from the University of Arizona.

What is Jeffrey G. Black's net worth?

The estimated net worth of Jeffrey G. Black is at least $202,500.00 as of August 11th, 2021. Mr. Black owns 25,000 shares of Apollo Endosurgery stock worth more than $202,500 as of November 30th. This net worth approximation does not reflect any other investments that Mr. Black may own. Learn More.

How do I contact Jeffrey G. Black?

The corporate mailing address for Mr. Black and other Apollo Endosurgery executives is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. Apollo Endosurgery can also be reached via phone at (512) 279-5100 and via email at [email protected]

Has Jeffrey G. Black been buying or selling shares of Apollo Endosurgery?

Jeffrey G. Black has not been actively trading shares of Apollo Endosurgery in the last ninety days. Most recently, on Wednesday, August 11th, Jeffrey G. Black bought 25,000 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $8.75 per share, with a total value of $218,750.00. Following the completion of the transaction, the chief financial officer now directly owns 25,000 shares of the company's stock, valued at $218,750.

Who are Apollo Endosurgery's active insiders?

Apollo Endosurgery's insider roster includes John Barr (Director), Jeffrey Black (CFO), Neil Gagnon (Major Shareholder), Chas Mckhann (CEO), and David Pacitti (Director).

Are insiders buying or selling shares of Apollo Endosurgery?

During the last twelve months, Apollo Endosurgery insiders bought shares 6 times. They purchased a total of 778,516 shares worth more than $5,851,714.51. During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 61,046 shares worth more than $466,133.82. The most recent insider tranaction occured on October, 15th when Major Shareholder Cpmg Inc bought 683,871 shares worth more than $5,300,000.25. Insiders at Apollo Endosurgery own 26.2 % of the company.

Information on this page was last updated on 10/15/2021.

Jeffrey G. Black Insider Trading History at Apollo Endosurgery

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2021Buy25,000$8.75$218,750.0025,000View SEC Filing Icon  
See Full Table

Jeffrey G. Black Buying and Selling Activity at Apollo Endosurgery

This chart shows Jeffrey G Black's buying and selling at Apollo Endosurgery by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apollo Endosurgery Company Overview

Apollo Endosurgery logo
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $8.10
Low: $8.00
High: $8.42

50 Day Range

MA: $9.18
Low: $8.23
High: $10.11

2 Week Range

Now: $8.10
Low: $3.10
High: $10.39

Volume

144,443 shs

Average Volume

246,027 shs

Market Capitalization

$232.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13
Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply